

Supplemental tables and figures

Table 1. Baseline characteristics based on renal function estimated by CKD-EPI (ml/min/1.73m²).

CKD-EPI renal function categories (ml/min/1.73m ²)	0-14	15-29	30-44	45-59	60-89	90-150	>150	All
All	660	3640	7489	9183	15532	4230	2	40736
Age (years), median (IQR)	81 (73-86)	83 (78-87)	82 (76-86)	79 (73-85)	74 (65-81)	60 (51-65)	18.5 (-)	77 (67-84)
Female	40.8%	48.7%	45.2%	41.1%	34.2%	25.1%	0.0%	38.2%
Diabetes	36.5%	35.9%	29.2%	24.6%	21.5%	21.9%	0.0%	25.2%
Hypertension	65.2%	57.8%	55.2%	51.5%	45.5%	36.4%	0.0%	49.1%
Ischemic heart disease	58.4%	59.9%	55.6%	51.4%	44.4%	35.1%	0.0%	48.7%
Married/Co-habitant	50.1%	46.3%	49.6%	54.5%	59.3%	62.3%	55.4%	52.7%
Duration of heart failure < 6 months	37.3%	34.5%	38.9%	48.5%	59.1%	68.5%	0.0%	51.4%
In-patient registration	89.1%	83.4%	74.2%	67.9%	61.9%	49.7%	50.0%	66.6%
Atrial fibrillation (history/on ecg)	45.6%	55.2%	57.7%	56.4%	49.8%	33.7%	0.0%	51.5%
ECG with atrial fibrillation	33.2%	41.4%	43.8%	43.2%	37.9%	24.9%	0.0%	39.1%
Device therapy								
Pacemaker	8.1%	12.2%	12.5%	10.6%	7.6%	3.9%	0.0%	9.2%
ICD/CRT/CRT-D	2.7%	3.2%	4.5%	3.9%	3.9%	4.7%	0.0%	4.0%
NYHA								
1	6.1%	5.7%	6.6%	9.2%	13.5%	19.1%	0.0%	11.2%
2	28.0%	32.5%	38.9%	44.8%	49.8%	51.5%	0.0%	45.3%
3	44.3%	49.9%	48.0%	41.6%	33.5%	27.3%	100.0%	38.6%
4	21.6%	11.9%	6.5%	4.4%	3.1%	2.1%	0.0%	4.8%
Echocardiography findings								
LVEF ≥50%	25.8%	27.4%	25.9%	23.9%	19.4%	14.7%	0.0%	21.8%
LVEF 40-49%	21.4%	20.2%	20.1%	20.6%	21.0%	20.0%	0.0%	20.5%
LVEF 30-39%	27.5%	24.8%	26.2%	27.4%	28.4%	29.2%	0.0%	27.6%
LVEF <30%	25.4%	27.7%	27.8%	28.2%	31.2%	36.1%	100.0%	30.1%
Treatment year								
2000-2006	22.7%	26.5%	24.3%	24.9%	20.9%	17.0%	0.0%	22.5%
2007-2012	77.3%	73.5%	75.7%	75.1%	79.1%	83.0%	100.0%	77.5%
Current medication								
ACEis/ARB	35.8%	58.7%	76.0%	82.9%	87.1%	92.1%	100.0%	81.3%
Beta-blockers	80.4%	83.4%	84.1%	85.2%	86.3%	89.3%	100.0%	85.6%
Loop-diuretic	23.6%	25.4%	27.1%	25.1%	24.6%	20.5%	50.0%	24.8%
Digoxin	5.8%	10.2%	16.3%	19.5%	20.3%	16.9%	0.0%	17.9%
Statins	37.8%	38.6%	42.3%	43.2%	44.4%	44.8%	0.0%	43.2%
Antiplateletes	59.4%	57.5%	54.6%	52.6%	50.3%	46.7%	0.0%	52.0%
Anticoagulants	17.4%	28.6%	36.2%	40.0%	39.3%	33.0%	0.0%	36.9%

IQR: interquartile range.

Table 2. Re-classification table: CKD-EPI equation compared with either a) Cockcroft-Gault or b) the MDRD equation for predicting one-year mortality at specific cut-points of <6%. 6-20% and >20% one-year mortality risk.

a)

	Model with Cockcroft-Gault (Cg)			
Patients with events	Cg < 6%	Cg 6-20%	Cg >20%	Total
CKD-EPI < 6%	113	31	0	144
CKD-EPI 6-20%	238	1334	1023	2595
CKD-EPI >20%	8	326	5158	5492
total	359	1691	6181	8231
Patients with no events	Cg < 6%	Cg 6-20%	Cg >20%	Total
CKD-EPI < 6%	1948	169	0	2117
CKD-EPI 6-20%	4152	10849	2957	17958
CKD-EPI >20%	45	2181	10202	12428
total	6145	13199	13159	32503

b)

	Model with Cockcroft-Gault (Cg)			
Patients with events	MDRD < 6%	MDRD 6-20%	MDRD >20%	Total
CKD-EPI < 6%	106	38	0	144
CKD-EPI 6-20%	131	2381	83	2595
CKD-EPI >20%	0	95	5397	5492
total	237	2514	5480	8231
Patients with no events	MDRD < 6%	MDRD 6-20%	MDRD >20%	Total
CKD-EPI < 6%	1103	1014	0	2117
CKD-EPI 6-20%	389	16712	859	17960
CKD-EPI >20%	0	214	12214	12428
total	1492	17940	13073	32505

Table 3. Agreement between renal function estimates with the CKD-EPI, MDRD, and the Cockcroft-Gault formula

a)

	CKD-EPI categories						
MDRD categories	0-14	15-29	30-44	45-59	60-89	90-150	>150
0-14	536	1	0	0	0	0	0
15-29	124	3074	28	0	0	0	0
30-44	0	565	6670	176	0	0	0
45-59	0	0	791	8457	701	0	0
60-89	0	0	0	550	13730	1104	0
90-150	0	0	0	0	1101	3062	0
>150	0	0	0	0	0	64	2
Agreement: 35531/40731 = 87.2%							
Kappa: 0.83 (0.83-0.83), p<0.001							

b)

	CKD-EPI categories						
CG categories	0-14	15-29	30-44	45-59	60-89	90-150	>150
0-14	440	149	1	0	0	0	0
15-29	216	2532	1621	248	8	0	0
30-44	4	889	4060	2843	791	0	0
45-59	0	65	1480	3640	3028	12	0
60-89	0	5	314	2272	7802	555	0
90-150	0	0	13	180	3773	2815	0
>150	0	0	0	0	130	848	2
Agreement: 21291/40731 = 52.3%							
Kappa 0.39 (0.38-0.39), p<0.001							

c)

	Cockcroft-Gault categories						
MDRD categories	0-14	15-29	30-44	45-59	60-89	90-150	>150
0-14	383	150	4	0	0	0	0
15-29	204	2228	721	65	8	0	0
30-44	3	1881	3763	1371	370	23	0
45-59	0	346	3129	3624	2538	307	5
60-89	0	20	961	3016	7047	4076	264
90-150	0	0	9	149	980	2349	676
>150	0	0	0	0	5	26	35
Agreement: 19429/40731 = 47.7%							
Kappa 0.33 (0.32-0.34), p<0.001							